Check out your Company Bowl for anonymous work chats.
Biocon Biologics is thrilled to have sponsored the Canadian Rheumatology Association’s (CRA) Annual Scientific Meeting in Winnipeg, Manitoba! We enjoyed meeting with HCPs and KOLs about how we’re working to increase access to biosimilars for Rheumatology patients in Canada.
Thank you, Jayasudha Nagarajan for the work you do here and the ways in which you have helped transform healthcare across the world!
Naveen Narayanan - Global CHRO at Biocon Biologics, is a visionary leader deeply connected to his roots and pioneering change in the world. Here, he is interviewed by Siddharth Ajmera from LinkedIn. Naveen makes a significant impact on numerous lives every day, extending his influence beyond business. Through this interview, we get a glimpse of his personal side beyond the role of CHRO at Biocon Biologics. It's truly inspiring to witness leaders extend their leadership beyond the professional realm, contributing to society wherever they go!
Embarking on a transformative journey in cancer care, Biocon Biologics stands at the forefront with its distinguished portfolio of oncology therapeutics. Among them, Biosimilar Pegfilgrastim are prescribed by doctors to reduce the risk of infection and side effects related to chemotherapy, empowering patients in their battle against cancer. At Biocon Biologics, we're committed to not only delivering innovative solutions but also fostering hope and support for those affected by cancer. Together, let's unite to #EndCancer, bridging the gap in care and amplifying awareness for a healthier tomorrow. #CancerAwareness #Support #Health #BioconBiologics #Innovation #Hope
We're delighted to announce that Biocon Biologics has been awarded the Best IPR Portfolio (Lifesciences) in the Large Enterprise category at the 3rd IP Excellence Awards and Global IP Conclave. The event, hosted by ASSOCHAM in New Delhi on February 6, 2024, marked our team's second consecutive win. Sahida Kamri , Manager, IPR, accepted the award from Hon’ble Justice Anish Dayal Judge, Delhi High Court. Pravin Anand, Chairperson of ASSOCHAM National Council on IPR & Managing Partner at Anand and Anand, John Cabeca U.S. Intellectual Property Counsel for South Asia, and Shirshendu Mukherjee, Mission Director at Grand Challenges India, BIRAC, were also present. This award recognizes our robust Intellectual Property ecosystem, underscoring our commitment to excellence. We're proud of our team's efforts in driving value creation for our stakeholders. 🏆 #IPExcellence #BioconBiologics
Karthik SM, the Global Head of Talent Acquisition at Biocon Biologics recently sat down with Medha Bhardwaj at LinkedIn to talk about how we are leveraging new-age technology and insights to make the right decisions when bringing in new talent for the company, across 25 different countries, as we scale up across the globe.
At BBL, Intellectual Capital is not just a set of intangible assets—it's a powerful force driving positive change in global healthcare. Harnessing the knowledge and expertise of our employees, we're making a tangible difference to affordable healthcare worldwide. Our commitment to intellectual capital goes beyond traditional definitions, as we leverage innovation and insights to shape the future of biologics. By empowering our team, fostering a culture of continuous learning, and embracing cutting-edge research, BBL stands at the forefront of intellectual capital. Join us on this journey of innovation and knowledge, where every idea contributes to a healthier, more accessible world. #BBLInnovation #IntellectualCapital #AffordableHealthcare
As we ended 2023 - a year marked by audacious goals, rigorous perseverance, and the unwavering spirit of those who dared to dream - Biocon Biologics' leaders reflected on their best memories of 2023, and told us what they are looking forward to, with their teams, in 2024. #BioconBiologics #BBLInnovators #LifeAtBBL #RowTogetherGrowTogetherBBL
Biocon Biologics Ltd today announced the successful completion of the transition of the acquired biosimilars business in ~120 countries across Advanced and Emerging Markets, a year ahead of schedule. Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a unique, fully integrated ‘lab to market’ biosimilars company committed to serving millions of patients across the globe. Earlier in 2023, over 70 Emerging Markets were integrated in July, the North America business transitioned in September and the European business in November. Biocon Biologics has made several key leadership appointments, built new capabilities and infrastructure from the ground up and set up dedicated teams to address the growing needs of patients and customers through self-led and partner or distributor-led commercial models. Biocon Biologics will now have a strong commercial footprint across ~120 countries with a direct presence in the United States, Canada, Europe and 9 key Emerging Market countries, namely India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines. A direct presence in these markets will enable the Company to get closer to patients and strengthen its relationships with prescribers and payers.
“Being highlighted by the report allowed us to improve access to our medicines, to Biocon Biologics’ medicines, in emerging economies, and improve awareness of our products and brands, in areas such as sub-Saharan Africa. And we have been very successful in this initiative, thanks to the report.” – Pritha Paul – Manager, Market Access–Emerging Economies, at Biocon Biologics We also collaborate with on-the-ground non-profit organizations like Action4Diabetes & Reach52, to set up wholistic approaches to manage integrated care for patients living with diabetes in emerging economies across the world. This work is very close to our heart as a company foundation whose singular focus is to leave no patient behind. Learn more about it by watching Pritha Paul’s interview with Access to Medicine Foundation.
